<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Buprenorphine: What's New</title>
      <link>http://buprenorphine.samhsa.gov/bwns/</link>
      <description>New information from SAMHSA's Buprenorphine Web Site</description>
      <language>en-us</language>
      <pubDate>Fri, 2 May 2008 08:30:00 EDT</pubDate>
      <lastBuildDate>Fri, 2 May 2008 08:30:00 EDT</lastBuildDate>
      <docs>http://blogs.law.harvard.edu/tech/rss</docs>
      <managingEditor>info@buprenorphine.samhsa.gov</managingEditor>
      <webMaster>webmaster@buprenorphine.samhsa.gov</webMaster>

<item>
         <title>Federal Register Notice</title>
         <link>http://buprenorphine.samhsa.gov/bwns/OMB-60day-DATA FR-11-04-2008.pdf</link>
         <description>
           The Office of Management and Budget seeks comment on the information collection burden as part of the process to renew the information collection authorization for "Form SMA-167: Notification of Intent to Use Schedule III, IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment of Opiate Addiction." The closing date for comments is January 5, 2009.</description>
         <pubDate>10 Nov 2008 16:10:00 EST</pubDate>
         <guid>http://buprenorphine.samhsa.gov/bwns/OMB-60day-DATA FR-11-04-2008.pdf</guid>
      </item>

<item>
         <title>Results from New Clinical Trial of Buprenorphine in Young Adults</title>
         <link>http://jama.ama-assn.org/cgi/content/full/300/17/2003</link>
         <description>
           This clinical trial evaluates the efficacy of continuing Buprenorphine-Naloxone for 12 weeks versus detoxification for opioid-addicted youth. The number of patients younger than 18 years was too small to analyze separately, but overall, patients in the detox group had higher proportions of opioid-poisitive urine test results at weeks 4 and 8 but not at week 12.</description>
         <pubDate>10 Nov 2008 11:44:00 EST</pubDate>
         <guid>http://jama.ama-assn.org/cgi/content/full/300/17/2003</guid>
      </item>   
<item>
         <title>SAMHSA and NIDA Convene Summit on Buprenorphine Treatment</title>
         <link>http://buprenorphine.samhsa.gov/bwns/presentations.html</link>
         <description>
           The Summit convened February 21-22, 2008, in Washington, D.C. to bring together experts in epidemiology,
           pharmacology, toxicology, and addiction treatment in order to build upon the findings of the previous summits in
           2003 and 2005.  Participants assessed the successes, progress and continued barriers to access to opioid treatment
           with buprenorphine.  Presentations identified best practices and useful clinical supports to enhance the quality of
           treatment.  Participants identified strategies to address emerging issues and concerns. SAMHSA and NIDA will prepare
           a report on the proceedings.
         </description>
         <pubDate>29 Feb 2008 09:22:00 EST</pubDate>
         <guid>http://buprenorphine.samhsa.gov/bwns/presentations.html</guid>
      </item>
      <item>
         <title>Update Physician Contact Information</title>
         <link>http://buprenorphine.samhsa.gov/pls/bwns/updtcntct2$.startup</link>
         <description>
           Physicians, you can now update your own contact information. If you have given permission to post contact information
           in the Buprenorphine Physician and Treatment Program Locator, the information will be updated there too.
         </description>
         <pubDate>29 Feb 2008 12:09:56 EST</pubDate>
         <guid>http://buprenorphine.samhsa.gov/pls/bwns/updtcntct2$.startup</guid>
      </item>
   </channel>
</rss>